Nascent Biotech, Inc. Featured in New Research Update

San Diego, CA, Jan. 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO), an emerging biotech company, with IND Clearance and IRB approval to begin Clinical trials for Brain Cancer, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.
The updated report provides an overview of recent events, new initiatives, and the Companya??s valuation relative to its peer group. A The sponsored research update also carries a rating and a price target and can be accessed and requested by email atA Arch Research notes that, a??With a number of competitive advantages in the space, Nascenta??s Primary Asset, Pritumumab, has several additional promising indications, a strong IP portfolio, and with beginning Phase I clinical studies, we believe that Nascent Biotech can enjoy hockey-stick type growth in the stock price within the next 3-6 months.a?? A About Nascent Biotech Inc.Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers.A  Its products are not commercially available. For further information please visit our websiteA
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2021    »